Lymphoma

Trial Protocol ID
D8227C00002_ACRUE

Investigator
John Wallmark, MD

A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)

Learn More